API Holdings (PharmEasy) Unlisted Shares Surge 53%: What’s Behind the Rally?

API Holdings unlisted share price has surged from ₹5.90 on September 9 to ₹9.00 as of September 14, 2026, marking a gain of approximately 52.5% in just five days. The sharp move comes immediately after the company's FY26 Annual Report was circulated to shareholders on September 8, bringing the latest financial and operational performance into focus.

API Holdings, the parent company of PharmEasy, has delivered a markedly improved set of FY26 numbers. Revenue has grown, EBITDA before exceptional items and ESOP expense has moved into positive territory, operating cash flow has turned positive, and the consolidated loss has narrowed substantially.

The company has also repaid ₹1,050 crore of outstanding debt, while the Docon merger has brought Thyrocare directly under API Holdings.

With the unlisted share price now at ₹9, investors are naturally asking whether the latest move represents a temporary rally or the beginning of a broader re-rating of API Holdings.

API Holdings Unlisted Share Price: From ₹5.90 to ₹9

The API Holdings unlisted share price has moved sharply in the past few days.

The timing is noteworthy. API Holdings’ latest financial results brought the company’s improved FY26 performance into focus, and its unlisted share price began rising from September 9 onwards.

The Annual Report provides investors with a detailed picture of API Holdings' financial performance and several important developments across the group.

The headline numbers show a clear improvement in the underlying business.

FY26 Financials Show a Major Improvement

API Holdings' consolidated revenue from operations increased from ₹5,872.2 crore in FY25 to ₹6,618.5 crore in FY26, representing growth of 12.7%.

More importantly, the company achieved a significant improvement in operating profitability.

API Holdings FY25 vs FY26

*EBITDA before exceptional items and ESOP expense.

The company's EBITDA before exceptional items and ESOP expense improved from a 3.0% negative margin in FY25 to a 1.5% positive margin in FY26.

At the same time, the consolidated loss declined by more than ₹1,000 crore.

This is one of the most important changes in the API Holdings story.

EBITDA Turns Positive

For years, one of the key questions around API Holdings has been whether the company can grow while improving its profitability.

The FY26 numbers provide a significant step in that direction.

EBITDA before exceptional items and ESOP expense increased from negative ₹179.1 crore in FY25 to positive ₹99.9 crore in FY26.

The company attributed the improvement to a combination of higher-margin business, better customer selection, improved gross-margin realisation, increased infrastructure utilisation and cost optimisation.

It also focused on reducing employee costs, rationalising warehouses and shutting down non-strategic, low-margin initiatives.

This means the company's improvement is not simply coming from higher revenue. API Holdings is also trying to improve the quality and profitability of that revenue.

API Holdings Is Still Loss-Making

Despite the sharp improvement in operating performance, API Holdings has not yet become profitable at the consolidated net-profit level.

The company reported a consolidated loss of ₹520.3 crore in FY26, compared with a loss of ₹1,572.4 crore in FY25.

This distinction is important.

API Holdings has achieved positive EBITDA before exceptional items and ESOP expense, but the company still needs to overcome finance costs, depreciation and other expenses before reaching sustained consolidated profitability.

Therefore, the current story is better described as an operating turnaround rather than a completed profitability turnaround.

For investors, the next major milestone will be seeing whether this operating improvement continues and eventually translates into consistent net profits.

Operating Cash Flow Turns Positive

Another important change is visible in API Holdings' cash flows.

Operating cash flow improved from an outflow of ₹210.9 crore in FY25 to an inflow of ₹77.2 crore in FY26.

This is significant because improving EBITDA becomes more meaningful when it starts translating into actual cash generation.

The company also reported an improvement in working-capital management.

Core working-capital days declined from 50 days in March 2025 to 42 days in March 2026.

API Holdings has therefore made progress on both operating profitability and cash generation, two areas that will remain important in determining whether the current turnaround can be sustained.

₹1,050 Crore Debt Repayment Changes the Story

The improvement in the business has been accompanied by a major change in the balance sheet.

API Holdings fully repaid the remaining ₹1,050 crore NCD facility, marking a major improvement in its balance sheet and making the company debt-free on this facility

The repayment was funded through proceeds from the sale of a portion of the Thyrocare stake along with internal accruals.

The debt reduction is particularly relevant because finance costs have been a significant burden on the company.

API Holdings' consolidated finance cost stood at ₹410 crore in FY26, compared with ₹506.1 crore in FY25.

With the ₹1,050 crore outstanding debt repaid, the company has removed a significant financial burden.

The key question going forward is how much of this improvement will flow through to the company's bottom line.

Docon Merger Brings Thyrocare Directly Under API Holdings

The latest corporate restructuring is another important development for investors.

The Docon Technologies and API Holdings merger was approved by the NCLT on August 31, 2026 and became effective on September 3, 2026.

Following the merger, Thyrocare Technologies became a direct subsidiary of API Holdings, with API Holdings directly holding 51.02% of Thyrocare.

The company said the merger was aimed at rationalising the group structure, improving operational synergies and management efficiency, reducing duplicate legal and regulatory compliances and enabling better utilisation of capital.

For API Holdings shareholders, the restructuring is important because Thyrocare is one of the group's most significant businesses.

Thyrocare Adds Another Strong Healthcare Business

The API Holdings story is no longer limited to PharmEasy.

Thyrocare has become an important part of the broader group, particularly given its scale in diagnostics.

During FY26, Thyrocare offered 1,275 diagnostic tests through 41 labs, conducted around 210 million tests and had an active franchisee base of more than 10,800.

The group also expanded its diagnostics presence through the PharmEasy marketplace, which recorded ₹158.8 crore in diagnostic revenue during FY26.

The direct ownership structure following the Docon merger therefore gives investors another important component to consider when evaluating API Holdings.

API Holdings Is More Than Just PharmEasy

The PharmEasy brand remains the most recognisable part of API Holdings, but the parent company has a much broader business portfolio.

The group operates across:

• Pharmaceutical distribution
• Retail and institutional supply
• Hospital supply
• Online healthcare
• Diagnostics
• Healthcare technology and related services

Retailio 1P generated ₹3,857.9 crore of revenue in FY26 and accounted for 68% of consolidated product revenue.

Revenue per retailer also increased from ₹54,000 in March 2025 to ₹63,000 in March 2026.

This shift towards a broader healthcare platform is an important part of understanding the API Holdings investment story today.

Why the Recent Rally Has Attracted Attention?

The recent API Holdings unlisted share price rally comes at a time when several important parts of the company's story have improved.

Revenue is growing.

FY26 revenue from operations increased 12.7% to ₹6,618.5 crore from ₹5,872.2 crore in FY25.

Operating profitability has improved.

EBITDA before exceptional items and ESOP expense moved from -3.0% of revenue in FY25 to +1.5% in FY26.

Losses have narrowed sharply.

The consolidated loss declined from ₹1,572.4 crore in FY25 to ₹520.3 crore in FY26.

Cash generation has improved.

Operating cash flow turned positive at ₹77.2 crore, compared with an outflow of ₹210.9 crore in FY25.

The balance sheet has strengthened.

API Holdings subsequently fully repaid the remaining ₹1,050 crore NCD facility.

The group structure has changed.

Following the Docon merger, Thyrocare became a direct subsidiary of API Holdings, with API Holdings directly holding 51.02% of Thyrocare.

Taken together, these developments provide an important backdrop to the renewed investor interest in API Holdings unlisted shares.

Is API Holdings Finally Turning Around?

The latest numbers point towards a meaningful operating turnaround, although the journey is not complete.

The improvement in EBITDA, cash flow and consolidated losses is clearly visible in the FY26 financial performance.

However, API Holdings is still reporting a consolidated loss of ₹520.3 crore.

For the turnaround to become sustainable, the company will need to demonstrate:

Consistent positive EBITDA

Sustained positive operating cash flow

Further reduction in losses

Eventual consolidated profitability

The ability to sustain these improvements will be much more important for the long-term API Holdings story than any short-term movement in its unlisted share price.

What Should API Holdings Unlisted Share Investors Watch Next?

The next few quarters will be important for determining whether the improvement reported in FY26 can be sustained.

Investors should closely track the following areas:

Profitability

Will API Holdings continue to improve EBITDA margins and move closer to consolidated profitability?

Cash Flow

Can the company maintain positive operating cash flow as the business grows?

PharmEasy

Can PharmEasy continue growing while improving its profitability and customer economics?

B2B Business

Can the Retailio and other B2B businesses continue to deliver sustainable growth while maintaining healthier margins?

Thyrocare

How will Thyrocare's continued performance contribute to the overall API Holdings business?

Capital Allocation

With the remaining ₹1,050 crore NCD facility fully repaid, how will API Holdings deploy its capital towards future growth?

API Holdings Unlisted Share Price: Key Takeaway

The API Holdings unlisted share price has risen from ₹5.90 on September 9 to ₹9.00 on September 14, 2026, delivering a gain of approximately 52.5%.

The sharp move followed the release of API Holdings' FY26 financial results, which highlighted a significant improvement in the company's operating performance.

Revenue increased 12.7%, EBITDA before exceptional items and ESOP expense turned positive, operating cash flow moved into positive territory and the consolidated loss narrowed substantially.

The company has also subsequently fully repaid its remaining ₹1,050 crore NCD facility, while the Docon merger has brought Thyrocare directly under API Holdings.

The bigger story for investors, therefore, is not just the recent price rise.

API Holdings is showing early signs of a shift from a growth-focused business towards a more profitability- and cash-flow-focused model.

The FY26 numbers show that this transition has begun, but the company still needs to demonstrate that the improvement can be sustained and eventually translate into consolidated profitability.

For investors tracking API Holdings unlisted shares, the next phase of the story will therefore be about execution — and whether the company's improving financial performance can support a sustained re-rating in the unlisted market.

Why is API Holdings unlisted share price rising?

API Holdings unlisted share price has risen sharply following the release of the company's FY26 financial results. The results highlighted a significant improvement in revenue, EBITDA, operating cash flow and consolidated losses. The company has also subsequently repaid its remaining ₹1,050 crore NCD facility and completed the Docon merger, further strengthening the overall business story.

Frequently Asked Questions

What is the API Holdings unlisted share price as of September 14, 2026?

The API Holdings unlisted share price is ₹9.00 as of September 14, 2026.

How much has API Holdings share price increased?

API Holdings unlisted share price has increased from ₹5.90 on September 9 to ₹9.00 on September 14, representing a gain of approximately 52.5%.

Is API Holdings profitable?

API Holdings has not yet achieved consolidated net profitability. It reported a consolidated loss of ₹520.3 crore in FY26. However, EBITDA before exceptional items and ESOP expense turned positive at ₹99.9 crore.

Has API Holdings repaid its debt?

API Holdings has fully repaid the remaining ₹1,050 crore NCD facility after the end of FY26. The company described itself as debt-free on this facility.

Does API Holdings own Thyrocare?

Yes. Following the Docon merger, API Holdings directly holds 51.02% of Thyrocare Technologies.

What is the relationship between PharmEasy and API Holdings?

PharmEasy is part of the API Holdings group. API Holdings is the broader parent company with businesses spanning online healthcare, pharmaceutical distribution, B2B healthcare supply, hospital supply and diagnostics.

What was API Holdings' FY26 revenue?

API Holdings reported consolidated revenue from operations of ₹6,618.5 crore in FY26, compared with ₹5,872.2 crore in FY25.

Is the API Holdings share price rally sustainable?

The sustainability of the rally will depend on whether API Holdings can continue improving EBITDA, cash generation and profitability. The FY26 numbers show meaningful progress, but the company remains loss-making at the consolidated level, making sustained execution important going forward.